Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels
David H. Henry(Pennsylvania Hospital), Peony Yu(FibroGen (United States)), Gopal Saha(FibroGen (United States)), Moshe Mittelman(Tel Aviv University), Pamela Bartels(FibroGen (United States)), Hetty E. Carraway(Cleveland Clinic), Charles W. Bradley(FibroGen (United States)), Amy Zhou(University of Saskatchewan), John A. Glaspy(University of California, Los Angeles), Robert Leong(FibroGen (United States)), Rosemary Harrup(University of Tasmania)
Cited by 6
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
|Blood|2019|369
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2016|297
Cancer Detection with Whole-Body PET Using 2-[18F]Fluoro-2-Deoxy-D-Glucose
|Journal of Computer Assisted Tomography|1993|255